SCHEMBL12136644

SCHEMBL12136644

[C-]#[N+]c1ccc(F)cc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.42
CES2 O00748 2/20 0.38
CES1 P23141 2/20 0.38
CA3 P07451 1/20 0.37
CA6 P23280 1/20 0.37
CA5A P35218 1/20 0.37
CA9 Q16790 1/20 0.37
CA14 Q9ULX7 1/20 0.37
CA5B Q9Y2D0 1/20 0.37
ATM Q13315 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
NFE2L2 Q16236 3/20 0.34
IDO1 P14902 2/20 0.34
AGXT P21549 2/20 0.34
CYP1A2 P05177 1/20 0.32
CYP2A6 P11509 1/20 0.32
KDM4E B2RXH2 3/20 0.31
MEN1 O00255 1/20 0.31
USP2 O75604 1/20 0.31
DHFR P00374 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29953631 1.00 ALDH1A1 (0.42) ALDH1A1CES2CES1CA3CA6
SCHEMBL29956184 0.80 CA3 (0.42) ALDH1A1CES2CES1CA3CA6
SCHEMBL12138250 0.76 NISCH (0.33) ALDH1A1CA3CA6CA5ACA9
SCHEMBL29954268 0.76 DGAT1 (0.39) ALDH1A1TDP1CYP2A6LMNAHPGD
SCHEMBL29952598 0.76 PKM (0.34) ALDH1A1CA3CA6CA5ACA9
SCHEMBL10252634 0.76 ESR1 (0.41)
SCHEMBL2628176 0.76 DGAT1 (0.39) ALDH1A1TDP1CYP2A6LMNAHPGD
SCHEMBL29954160 0.76 CCR2 (0.34) ALDH1A1TDP1CYP2A6LMNAKMT2A
SCHEMBL2741041 0.76 ACHE (0.35) ALDH1A1CA3CA6CA5ACA9
SCHEMBL11862205 0.75 ALDH1A1 (0.42) ALDH1A1CES2CES1CA3CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170260204-A1 POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE GILEAD SCIENCES, INC. 2017-09-14 US disclosed
US-9732092-B2 Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections GILEAD SCIENCES, INC. (US) 2017-08-15 US disclosed
US-9663528-B2 Substituted 1,2,3,4,6,8,12,12a-octahydro-1,4-methanodipyrido[1,2-a:1',2'-d]pyrazines and methods for treating viral infections GILEAD SCIENCES, INC. (US) 2017-05-30 US disclosed
US-20170057976-A1 POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE GILEAD SCIENCES, INC. 2017-03-02 US disclosed
US-20160176885-A1 SUBSTITUTED 1,2,3,4,6,8,12,12a-OCTAHYDRO-1,4-METHANODIPYRIDO[1,2-a:1',2'-d]PYRAZINES AND METHODS FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2016-06-23 US disclosed
US-9216996-B2 Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections GILEAD SCIENCES, INC. (US) 2015-12-22 US disclosed
US-20140221356-A1 POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE GILEAD SCIENCES, INC. 2014-08-07 US disclosed
US-20110282059-A1 Light emitting material for use as host dopant in emissive layer for OLEDs SOLVAY SA (BE) 2011-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160176885-A1 SUBSTITUTED 1,2,3,4,6,8,12,12a-OCTAHYDRO-1,4-METHANODIPYRIDO[1,2-a:1',2'-d]PYRAZINES AND METHODS FOR TREATING VIRAL INFECTIONS PYM1, ZC3HAV1, ZYX ALDH1A1 735/4885CES2 1689/4885CES1 1085/4885
US-20110282059-A1 Light emitting material for use as host dopant in emissive layer for OLEDs APOL1, OPRM1, OCIAD1 ALDH1A1 514/4885CES2 954/4885CES1 1178/4885
US-20140221356-A1 POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE ZC3HAV1, PYM1, ZC3HAV1L ALDH1A1 3173/4885CES2 175/4885CES1 562/4885
US-20170057976-A1 POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE ZC3HAV1, PYM1, ZC3HAV1L ALDH1A1 3173/4885CES2 175/4885CES1 562/4885
US-20170260204-A1 POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE ZC3HAV1, PYM1, ZC3HAV1L ALDH1A1 3173/4885CES2 175/4885CES1 562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.